Ivosidenib(Tibsovo) is indicated for use in adult patients with relapsed or refractory acute myeloid leukemia (AML) who are susceptible to Ivosidenib dehydrogenase-1 (IDH1) mutations using a well-validated test and should be used with the following precautions.

What do I need to pay attention to when using Tibsovo?

When using Ivosidenib(Tibsovo), patients need to pay extra attention to the following aspects to ensure that the treatment goes smoothly.

Strictly follow the doctor's instructions

The dose, timing and frequency of Ivosidenib must be administered in strict accordance with the doctor's instructions. Patients should not increase or decrease the dose or change the duration of the drug on their own, so as not to affect the effect of treatment or increase the risk of adverse effects.

Health monitoring

During the use of Ivosidenib, patients should undergo regular health monitoring, including blood tests, liver function tests, and related tests such as electrocardiograms. These tests help doctors detect and manage any potential medication side effects or complications in a timely manner.

Drug interactions

Ivosidenib may interact with other medications, affecting the drug's efficacy or increasing the risk of adverse effects. While taking Ivosidenib, people should tell their doctor about other medications they are taking, including prescription medications, over-the-counter medications, and supplements. Your doctor will evaluate potential drug interactions based on your specific situation and make recommendations accordingly.

Pay attention to adverse reactions

Ivosidenib may cause a variety of adverse reactions, such as headache, nausea, fatigue, leukocytosis, arthralgia, diarrhea, dyspnea, rash, etc. Patients should pay close attention to their physical reactions and inform their doctor if they experience any discomfort. The doctor will adjust the treatment plan or give appropriate treatment according to the patient's specific situation.

Precautions for special populations

The safety of Ivosidenib in pregnant and lactating women has not been established, and pregnant and lactating women should consult their doctor and inform themselves of their medical condition before using Ivosidenib. If you become pregnant or plan to become pregnant during use, you should inform your doctor immediately. Ivodonib may cause adverse effects on the liver, patients should inform their doctor of their history of liver disease before using Ivosidenib, monitor liver function regularly during the medication, and inform the doctor immediately if symptoms of abnormal liver function occur.

The duration of treatment with Ivosidenib may be long, and patients should stick to taking the drug on time and avoid discontinuing or interrupting the drug on their own. If you need to stop the medication or discontinue treatment for a special reason, you should consult your doctor and follow your doctor's advice.